Flexion Therapeutics (NASDAQ:FLXN) Upgraded to “Sell” at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Flexion Therapeutics (NASDAQ:FLXN) from a strong sell rating to a sell rating in a report issued on Saturday, BidAskClub reports.

FLXN has been the topic of several other reports. ValuEngine upgraded shares of Flexion Therapeutics from a sell rating to a hold rating in a research note on Thursday, May 23rd. Benchmark upgraded shares of Flexion Therapeutics from a hold rating to a buy rating and set a $19.00 target price on the stock in a research note on Thursday, May 9th. Zacks Investment Research upgraded shares of Flexion Therapeutics from a sell rating to a hold rating in a research note on Friday, May 10th. Finally, Northland Securities reiterated a buy rating and issued a $20.00 target price on shares of Flexion Therapeutics in a research note on Thursday, May 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. Flexion Therapeutics currently has an average rating of Buy and a consensus target price of $23.57.

Shares of FLXN stock opened at $11.92 on Friday. The stock has a market cap of $426.79 million, a PE ratio of -2.65 and a beta of 1.37. The company has a quick ratio of 7.33, a current ratio of 7.80 and a debt-to-equity ratio of 3.95. The company’s 50 day simple moving average is $10.73. Flexion Therapeutics has a 12 month low of $8.76 and a 12 month high of $24.10.

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.96) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.06) by $0.10. Flexion Therapeutics had a negative net margin of 368.31% and a negative return on equity of 175.29%. The company had revenue of $16.95 million for the quarter, compared to analysts’ expectations of $14.03 million. On average, sell-side analysts anticipate that Flexion Therapeutics will post -3.99 EPS for the current fiscal year.

In other news, insider Michael D. Clayman bought 2,317 shares of the stock in a transaction on Thursday, August 8th. The shares were acquired at an average cost of $10.85 per share, for a total transaction of $25,139.45. Following the purchase, the insider now directly owns 72,249 shares of the company’s stock, valued at approximately $783,901.65. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director C Ann Merrifield bought 8,000 shares of the stock in a transaction on Thursday, May 23rd. The stock was purchased at an average price of $12.64 per share, for a total transaction of $101,120.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $126,400. The disclosure for this purchase can be found here. Insiders acquired a total of 14,817 shares of company stock worth $175,364 over the last quarter. Corporate insiders own 16.01% of the company’s stock.

Large investors have recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Flexion Therapeutics by 46.2% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 106,164 shares of the specialty pharmaceutical company’s stock worth $1,325,000 after buying an additional 33,569 shares during the last quarter. Claro Advisors LLC increased its holdings in shares of Flexion Therapeutics by 33.0% in the 1st quarter. Claro Advisors LLC now owns 22,150 shares of the specialty pharmaceutical company’s stock worth $276,000 after buying an additional 5,500 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Flexion Therapeutics by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 384,433 shares of the specialty pharmaceutical company’s stock worth $4,351,000 after buying an additional 7,814 shares during the last quarter. Alps Advisors Inc. increased its holdings in shares of Flexion Therapeutics by 4.5% in the 1st quarter. Alps Advisors Inc. now owns 91,439 shares of the specialty pharmaceutical company’s stock worth $1,141,000 after buying an additional 3,952 shares during the last quarter. Finally, Campbell Capital Management Inc. bought a new position in shares of Flexion Therapeutics in the 2nd quarter worth $1,594,000. 89.12% of the stock is currently owned by hedge funds and other institutional investors.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Featured Article: What is a good dividend yield?

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Juniper Networks, Inc.  To Go Ex-Dividend on September 3rd
Juniper Networks, Inc. To Go Ex-Dividend on September 3rd
Juniper Networks, Inc.  To Go Ex-Dividend on September 3rd
Juniper Networks, Inc. To Go Ex-Dividend on September 3rd
Medical Developments International Ltd to Issue Final Dividend of $0.02
Medical Developments International Ltd to Issue Final Dividend of $0.02
Qantas Airways Limited Announces Final Dividend of $0.13
Qantas Airways Limited Announces Final Dividend of $0.13
Burlington Stores  Posts Quarterly  Earnings Results, Beats Estimates By $0.21 EPS
Burlington Stores Posts Quarterly Earnings Results, Beats Estimates By $0.21 EPS
Abercrombie & Fitch  Posts  Earnings Results, Beats Expectations By $0.04 EPS
Abercrombie & Fitch Posts Earnings Results, Beats Expectations By $0.04 EPS


 
© 2006-2019 Zolmax.